Skip to main content

Table 4 Patient Outcomes: lipid panel variations, patients who have reached their lipid goals and incidence rate of cardiovascular events and all-cause mortality

From: Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis

Group Brand-name Generic Total p
Number of patients (%) 3007 (22.7%) 10,237 (77.3%) 13,244 (100%)
Clinical chemistry parameters
 Total cholesterol, mg/dL; initial 223.9 [222.7–225.1] 223.2 [222.4–224.0] 223.3 [222.8–223.8] 0.489
 Total cholesterol, mg/dL; final 189.4 [188.1–190.7] 192.8 [191.9–193.7] 192.0 [191.4–192.6] < 0.001
 Difference (initial – final) −34.5 −30.4 −31.3 < 0.001
 Triglycerides, mg/dL; initial 141.7 [140.2–143.2] 142.5 [141.6–143.4] 142.3 [141.7–142.9] 0.619
 Triglycerides, mg/dL: final 129.8 [128.5–131.1] 133.8 [133.1–134.5] 132.9 [132.4–133.4] 0.014
 Difference (initial – final) −11.9 −8.7 −9.4 < 0.001
 High-density lipoprotein cholesterol, mg/dL; initial 50.1 [48.3–51.9] 50.2 [49.0–51.4] 50.2 [49.3–51.1] 0.993
 High-density lipoprotein cholesterol, mg/dL; final 55.7 [53.8–57.6] 54.3 [53.0–55.6] 54.5 [53.6–55.4] < 0.001
 Difference (initial – final) 5.6 4.1 4.3 0.035
 Low-density lipoprotein cholesterol, mg/dL; initial 135.6 [133.7–137.5] 135.1 [133.6–136.6] 135.2 [134.3–136.1] 0.485
 Low-density lipoprotein cholesterol, mg/dL; final 118.6 [116.8–120.4] 121.5 [120.1–123.0] 120.8 [120.2–121.4] < 0.001
 Difference (initial – final) −17.0 −13.6 −14.4 < 0.001
Patients who have reached LDL-c goal (%)*
 At the start of statin therapy 17.9 [16.5–19.3] 17.7 [16.9–18.4] 17.7 [17.1–18.4] 0.811
 At discontinuation 42.0 [40.2–43.7] 39.2 [38.3–40.2] 39.9 [39.0–40.7] OR; 0.87 [0.80–0.95], p = 0.003
 Absolute variation 24.1 21.5 22.2 < 0.001
Patient Outcomes (IR)**
- Any cardiovascular event 31.48 [27.85–35.46] 39.56 [37.24–41.99] 37.63 [35.65–39.69] < 0.001
­ CHD event 14.41 [11.98–17.18] 18.76 [17.17–20.45] 17.71 [16.36–19.14] 0.008
­ Stroke 17.08 [14.43–20.07] 20.81 [19.13–22.59] 19.91 [18.48–21.43] 0.033
- All-cause mortality 18.82 [16.03–21.95] 25.09 [23.25–27.04] 23.59 [22.03–25.23] < 0.001
  1. Values expressed as mean with standard deviation or 95% confidence interval in brackets, CHD: Coronary Heart Disease; IR: unadjusted cumulative incidence rate in number of cases per 1000 person-years, *OR: Odds ratio, adjusted by age, sex, number of comorbidities, Charlson index, resource utilization band (RUB), proportion of subjects reaching their LDL-cholesterol (LDL-c) goal at the start of therapy, statin type and prior cardiovascular event; **p values using the Mantel-Haenszel Chi-square test